In vitro activity of free and liposomal nystatin against Leishmania species in comparison with several ampbotericin B and azolic formulations

  1. Piñero, J. 1
  2. Martínez, E. 1
  3. Ortega, A. 1
  4. Del Castillo, A. 1
  5. Valladares, B. 1
  1. 1 Universidad de La Laguna
    info

    Universidad de La Laguna

    San Cristobal de La Laguna, España

    ROR https://ror.org/01r9z8p25

Journal:
Revista Ibérica de Parasitología

ISSN: 0034-9623

Year of publication: 2003

Volume: 63

Issue: 3-4

Pages: 93-96

Type: Article

GOOGLE SCHOLAR

More publications in: Revista Ibérica de Parasitología

Sustainable development goals

Abstract

The sensitivities of promastigote stages of three species of Leishmania were determined in vitro to nystatin, liposomal formulations ofnystatin, other amphotericin B formulations and antimycotic azole drugs. Liposomal formulations ofnystatin were more active than free nystatin against L. braziliensis strains but less active against L. infantum and L. tropica.

Bibliographic References

  • Ali, S.A., Iqbal, J., Nabeel, Khalil, Y., Manzoor, A., Bukhari, 1., Ahmad, B. and Yasinzai, M.M. 1997. Leishmanicidal activity of Nystatin (mycostatin): a potent polyene compound. J Pak Med Assoc, 47, 246-248.
  • Arikan, S. and Rex, 1.H. 2001. Nystatin LF (Aronex/Abbot). Curr Opin Investig Drugs, 2, 488-495.
  • Desjeux P. and UNAIDS. Leishmania and HIV in gridlock. Geneva, World Health Organization and UNAIDS, 1998, WHO/CTDILEISH/98.9 and UNATDS/98.23
  • Jolmson, E.M., Ojwang, 1.0., Szekely, A., Wallace, T.L. and Warnock, D.W. 1998. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother, 42, 1412-1416.
  • Mehta, R.T., Hopfer, R.L., Gunner, L.A., .luliano, R.L. and LopezBerestein, G. 1987. Formulation, toxicity, and antifungal activity m vitl'o of liposome-encapsulated nystatin as thel'apeutic agent fol' systemic candidiasis. Antimicrob Agents Chemother, 31,1897-1900.
  • Oakley, K.L. , Moore, C.B. and Denning, D.W. 1999. Compal'ison of in vitl'o activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotel'icin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother, 43 , 1264-1266.
  • Piñero, l.E., Martínez, S., Del Castillo, A , Portús, M. and Valladares, B. 2002. In vitro susceptibility of Leishmania infantum strains isolated from Spanish HIV-positive patients to Abelcet and Fungizone. J Antimicrob Chemother, 50, 304-306.
  • Richardson, M.D. and Warnock, D.W. 1997. Fungal infection: diagnosis and management, 2nd ed. Blackwell Scientific Publications, Oxford, United Kingdom.
  • Tincusi, B.M., limenez, LA., Bazzocchi, LL., Moujir, L.M., Mamani, Z.A , Piñero, l, Ravelo, AG. and Valladares, B. 2002. Antimicrobial terpenoids from the oleoresin of the Peruvian medicinal plant Copaifera paupera. Planta Med, 68, 808-812.
  • Wallace, T.L., Paetznick, V., Cossum, P.A, Lopez-Berestein, G., Rex, lH. and Anaissie, E. 1997. Activity of liposomal nystatin against disseminated Aspergillus fumiga tus infection in neutropenic mice Antimicrob Agents Chemother, 41 , 2238-2243.
  • Yardley, V. and Croft, S.L. 2000. A comparison ofthe activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrab Agents, 13, 243-248.
  • Yardley, V. and Croft, S.L. 1999. In vitra and in viva activity of amphotel'icin B-lipid formulations against experimental Trypanasama cruzi infections. Am J Trap Med Hyg, 61, 193-197